Francesco Onida, Nico Gagelmann, Yves Chalandon, Guido Kobbe, Marie Robin, Argiris Symeonidis, Theo M de Witte, Raphaël A Itzykson, Madlen Jentzsch, Uwe Platzbecker, Valeria Santini, Guillermo F Sanz, Christoph Scheid, Eric Solary, Peter Valent, Raffaela Greco, Isabel Sánchez-Ortega, Ibrahim Yakoub-Agha, Lisa Pleyer
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly as patients with CMML are mostly older and comorbid. Therefore, the decision between a non-intensive treatment approach and allo-HCT represents a delicate balance, especially since prospective randomized studies are lacking and retrospective data in the literature is conflicting...
March 17, 2024: Blood